Correspondence 0001104659-23-114381 from PSYENCE BIOMEDICAL LTD. (PBM)
PSYENCE BIOMEDICAL LTD.
Date: Nov. 3, 2023 · CIK: 0001985062 · Accession: 0001104659-23-114381
AI Filing Summary & Sentiment
Reasoning
Letter
Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Jimmy McNamara and Alan Campbell
Dear Mr. McNamara and Mr. Campbell:
Psyence Biomedical Ltd., a corporation organized under the laws of Ontario (the “Company,” “we,” “our” or “us”), hereby transmits the Company’s response to the comment letter received from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) dated October 25, 2023, regarding Amendment No.2 to the Company’s Registration Statement on Form F-4 filed with the Commission on October 16, 2023 (the “Registration Statement”). For the Staff’s convenience, we have repeated below each of the Staff’s comments in bold and have followed such comments with the Company’s response.
Amendment No. 2 to Registration Statement on Form F-4
Questions and Answers about the Business Combination
Who is Psyence?, page 7
1. We note your response to prior comment 2 and re-issue in part. Please revise the Q&A to remove citations to clinical data and trials of PEX010 from trials that are not conducted or sponsored by Psyence.
In response to the Staff’s comment, the Company has revised the Q&A and Information About Psyence sections in Amendment No. 3 to the Registration Statement to remove citations to clinical data and trials of PEX010 from trials that are not conducted or sponsored by Psyence.
We thank the Staff for its review of the foregoing and the Registration Statement. If you have further comments, please feel free to contact NCAC’s legal counsel, Ari Edelman, at aedelman@mwe.com or by telephone at (212) 547-5372 .
Sincerely,
By: /s/ Dr. Neil Maresky
Show Raw Text
CORRESP 1 filename1.htm November 3, 2023 U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Jimmy McNamara and Alan Campbell Dear Mr. McNamara and Mr. Campbell: Psyence Biomedical Ltd., a corporation organized under the laws of Ontario (the “Company,” “we,” “our” or “us”), hereby transmits the Company’s response to the comment letter received from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) dated October 25, 2023, regarding Amendment No.2 to the Company’s Registration Statement on Form F-4 filed with the Commission on October 16, 2023 (the “Registration Statement”). For the Staff’s convenience, we have repeated below each of the Staff’s comments in bold and have followed such comments with the Company’s response. Amendment No. 2 to Registration Statement on Form F-4 Questions and Answers about the Business Combination Who is Psyence?, page 7 1. We note your response to prior comment 2 and re-issue in part. Please revise the Q&A to remove citations to clinical data and trials of PEX010 from trials that are not conducted or sponsored by Psyence. In response to the Staff’s comment, the Company has revised the Q&A and Information About Psyence sections in Amendment No. 3 to the Registration Statement to remove citations to clinical data and trials of PEX010 from trials that are not conducted or sponsored by Psyence. We thank the Staff for its review of the foregoing and the Registration Statement. If you have further comments, please feel free to contact NCAC’s legal counsel, Ari Edelman, at aedelman@mwe.com or by telephone at (212) 547-5372 . Sincerely, By: /s/ Dr. Neil Maresky Name: Dr. Neil Maresky Title: Chief Executive Officer, Psyence Biomedical Ltd.